Newsroom

YAKESHI, China--(BUSINESS WIRE)--A Changan Automobile realizou um evento de lançamento com o tema “Atualização da Inteligência SDA da Changan e Lançamento Global da Estratégia de Baterias de Sódio-Íon”, na cidade de Yakeshi, Mongólia Interior. Durante o evento, a Changan apresentou oficialmente sua estratégia global para baterias de sódio-íon e anunciou o início da Temporada Global de Testes 2026. A Changan está acelerando o desenvolvimento da tecnologia de baterias de sódio-íon como parte de s...

YAKESHI, China--(BUSINESS WIRE)--Changan Automobile held a release event themed “Changan SDA Intelligence Update & Global Launch of Sodium-Ion Battery Strategy” in Yakeshi, Inner Mongolia. During the event, Changan formally unveiled its global sodium-ion battery strategy and announced the commencement of its 2026 Global Testing Season. Changan is accelerating the advancement of sodium-ion battery technology as part of its global battery strategy. Tan Benhong, Chief Brand Officer of China Ch...

YAKESHI, Chine--(BUSINESS WIRE)--Changan Automobile a organisé un événement à Yakeshi, en Mongolie-Intérieure, autour du thème « Mise à jour de l’intelligence SDA & Lancement mondial de la stratégie des batteries sodium-ion ». À cette occasion, le constructeur a officiellement dévoilé sa stratégie mondiale en matière de batteries sodium-ion et annoncé le lancement de sa Saison Mondiale d’Essais 2026. Dans le cadre de sa stratégie globale sur les batteries, Changan accélère le développement...

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today new late-breaking data from the Phase III FENtrepid study showing the investigational Bruton’s tyrosine kinase (BTK) inhibitor fenebrutinib met its primary endpoint of non-inferiority compared to Ocrevus® (ocrelizumab) in reducing disability progression in patients with primary progressive multiple sclerosis (PPMS). Fenebrutinib showed a 12% reduction in the risk of...

NEW YORK--(BUSINESS WIRE)--Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Hub Group, Inc. (“Hub Group” or the “Company”) (NASDAQ: HUBG). Faruqi & Faruqi is a leading national securities law firm with offices in New York, Pennsylvania, California and Georgia. The firm has recovered hundreds of millions of dollars for investors since its founding in 1995. See www.faruqilaw.com. On February 6, 2026, Hub Group shares fell sharply, aft...

KUWAIT CITY--(BUSINESS WIRE)--DCO concludes 5th General Assembly with adoption of the Kuwait Declaration on Responsible AI for Global Digital Prosperity...

NEW YORK--(BUSINESS WIRE)--Rosen Law Firm, a global investor rights law firm, reminds investors about a class action lawsuit on behalf of purchasers of common stock of Integer Holdings Corporation (NYSE: ITGR) between July 25, 2024 and October 22, 2025. Integer is a medical device contract manufacturer. For more information, submit a form, email attorney Phillip Kim, or give us a call at 866-767-3653. The Allegations: Rosen Law Firm is Investigating the Allegations that Integer Holdings Corpora...

HYDERABAD, India--(BUSINESS WIRE)--Tanla today announced a major impact milestone for Wisely Ai, following an impact celebration event hosted by Indosat Ooredoo Hutchison in Indonesia....

PALO ALTO, Calif.--(BUSINESS WIRE)--Honda Motor Co., Ltd. and Mythic announce a joint development agreement in which Honda R&D Co. Ltd., the R&D subsidiary of Honda, will license Mythic’s Analog Processing Unit (APU) technology and the companies will co-develop an automotive-grade AI SOC for deployment in Honda’s next-generation software-defined vehicles (SDVs) by the late 2020s/early 2030s. In line with Honda’s safety approach, Mythic’s intelligent, ultra-efficient analog compute-in-me...

ニューオーリンズ＆ヨクネアム（イスラエル）--(BUSINESS WIRE)--（ビジネスワイヤ） -- 能動血管内デバイスのリーディングカンパニーであるラピッド・メディカル™は、DISTALS多施設共同無作為化対照試験からの最新の結果を発表しました。この試験では、中等度血管閉塞（MVO）脳卒中において、TIGERTRIEVER™ 13が内科的治療と比較して、優れた脳組織再灌流と安全性プロファイルを実現できることが示されました。この結果は、2026年国際脳卒中会議（ISC）のメイン閉会セッションで発表されました。 トップライン結果では、TIGERTRIEVER™ 13を適用した群は、薬物療法群と比較して症候性頭蓋内出血（sICH）を伴わない再灌流成功率が3倍高く、86.3%対27.7%（p < 0.001）との結果となりました。特筆すべきは、TIGERTRIEVER 13を投与された無作為化治療群では、sICHイベントが報告されなかったことです。比較においては、静脈内血栓溶解療法のみで報告されたsICH発生率は、最近の試験では2～6%と高くなっています1,2,3。 DISTAL...